Targeted therapy of CML with imatinib mesylate (IM) or other inhibitors of the BCR-ABL oncoprotein is the current therapy of choice for patients with CP disease, although IM does not always produce durable remissions [5,6]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.